SCHEMBL7080809

SCHEMBL7080809

Cc1ccc(C(=O)N(C)C)c(Oc2ccc3c(=O)cc(-c4ccccc4Oc4c(C(=O)N(C)C)ccc(C)c4C)oc3c2)c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
GAA P10253 1/20 0.43
RAB9A P51151 1/20 0.43
AR P10275 1/20 0.41
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
CYP3A4 P08684 2/20 0.40
TP53 P04637 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 2/20 0.40
TNKS O95271 1/20 0.40
CYP19A1 P11511 1/20 0.40
SIGMAR1 Q99720 1/20 0.39
HPGD P15428 2/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
ACHE P22303 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7207949 0.73 MEN1 (0.53) KDM4EALDH1A1MAPTNPC1GAA
SCHEMBL7081030 0.72 AR (0.60) KDM4EALDH1A1MAPTNPC1GAA
SCHEMBL7075370 0.69 KDM4E (0.53) KDM4EALDH1A1MAPTNPC1GAA
7,2'-Dimethoxyflavone SCHEMBL4285153 0.69 AR (0.81) KDM4EALDH1A1MAPTNPC1GAA
SCHEMBL7075686 0.66 HPGD (0.56) KDM4EALDH1A1MAPTNPC1RAB9A
SCHEMBL7080450 0.66 BCHE (0.52) KDM4EALDH1A1MAPTNPC1GAA
SCHEMBL7075361 0.65 AR (0.65) KDM4EALDH1A1MAPTNPC1GAA
SCHEMBL14146408 0.64 ALDH1A1 (0.66) KDM4EALDH1A1MAPTNPC1GAA
SCHEMBL4650574 0.63 HPGD (0.81) KDM4EALDH1A1MAPTNPC1RAB9A
SCHEMBL7127255 0.63 KDM4E (0.73) KDM4EALDH1A1MAPTNPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610738-B2 Treatment of Alzheimer's Disease by combining both acetylcholinesterase inhibitory activity and antioxidant activity (by virtue of their carbamoyl and flavonoid pharmacophores) BIOGAL PHARMACEUTICAL CO., LTD. (HU) 2003-08-26 US claimed
US-6610738-B2 Treatment of Alzheimer's Disease by combining both acetylcholinesterase inhibitory activity and antioxidant activity (by virtue of their carbamoyl and flavonoid pharmacophores) BIOGAL PHARMACEUTICAL CO., LTD. (HU) 2003-08-26 US disclosed
EP-1322632-A1 N-DISUBSTITUTED CARBAMOYLOXY FLAVONES Biogal Pharmaceutical Co., Ltd (HU) 2003-07-02 EP disclosed
US-20020128494-A1 N-Disubstituted carbamoyloxy flavones BIOGAL PHARMACEUTICAL CO., LTD. (HU) 2002-09-12 US disclosed
WO-2002024677-A1 N-DISUBSTITUTED CARBAMOYLOXY FLAVONES BIOGAL PHARMACEUTICAL CO., LTD. (HU) 2002-03-28 WO disclosed
WO-2002024676-A1 N-DISUBSTITUTED CARBAMOYLOXY FLAVONES TEVA PHARMACEUTICALS INDUSTRIES, LTD. (IL) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128494-A1 N-Disubstituted carbamoyloxy flavones CBR3, FOS, CBR1 KDM4E 366/4885ALDH1A1 3001/4885MAPT 3319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.